Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase III Copanlisib in Rituximab-refractory iNHL (CHRONOS-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02369016
Recruitment Status : Active, not recruiting
First Posted : February 23, 2015
Last Update Posted : April 27, 2022
Information provided by (Responsible Party):

Brief Summary:
To assess the safety of copanlisib.

Condition or disease Intervention/treatment Phase
Lymphoma, Non-Hodgkin Drug: Copanlisib (BAY 80-6946) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Actual Study Start Date : September 22, 2015
Estimated Primary Completion Date : November 23, 2022
Estimated Study Completion Date : November 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Copanlisib (BAY 80-6946)
patients with rituximab-refractory iNHL
Drug: Copanlisib (BAY 80-6946)
60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle

Primary Outcome Measures :
  1. Number of patients with treatment-emergent adverse events [ Time Frame: Up to 3 years ]
  2. Number of patients with serious adverse events [ Time Frame: Up to 3 years ]
  3. Number of patients with abnormal lab parameters [ Time Frame: Up to 3 years ]
  4. Number of patients with abnormal vital signs [ Time Frame: Up to 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:

    • Follicular lymphoma (FL) grade 1-2-3a.
    • Small lymphocytic lymphoma (SLL) with absolute lymphocyte count < 5 x 10*9/L at the time of diagnosis and at study entry.
    • Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM).
    • Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal).
  • Patients must have received two or more prior lines of treatment. A previous regimen is defined as one of the following: at least two months of single-agent therapy, at least two consecutive cycles of polychemotherapy, autologous transplant, radioimmunotherapy.
  • Prior therapy must include rituximab and alkylating agents.Prior exposure to idelalisib or other PI3K inhibitors is acceptable (except to copanlisib) provided that there is no resistance.
  • Patients must be refractory to the last rituximab-based treatment, defined as no response or response lasting < 6 months after completion of treatment. Time interval to assess refractoriness will be calculated between the end date (last day) of the last rituximab-containing regimen and the day of diagnosis confirmation of the subsequent relapse.
  • Patients must have at least one bi-dimensionally measurable lesion (which has not been previously irradiated) according to the Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.
  • Patients affected by WM, who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment, must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ≥ 2 x upper limit of normal (ULN)and positive immunofixation test.
  • ECOG performance status ≤ 1
  • Adequate bone marrow, liver and renal function

Exclusion Criteria:

  • Histologically confirmed diagnosis of FL grade 3b.
  • Chronic lymphocytic leukemia (CLL).
  • Transformed disease (assessed by investigator):

    • histological confirmation of transformation, or
    • clinical and laboratory signs: rapid disease progression, high standardized uptake value (SUV) (> 12) by positron emission tomography (PET) at baseline if PET scans are performed (optional).
  • Bulky disease - Lymph nodes or tumor mass (except spleen) >= 7cm LD (longest diameter)
  • Known lymphomatous involvement of the central nervous system.
  • Uncontrolled arterial hypertension despite optimal medical management (per investigator's assessment).
  • Type I or II diabetes mellitus with HbA1c > 8.5% at Screening.
  • Known history of human immunodeficiency virus (HIV) infection.
  • Active clinically serious infections > CTCAE Grade 2
  • Active Hepatitis B or hepatitis C
  • History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
  • History of having received an allogeneic bone marrow or organ transplant
  • Positive cytomegalovirus (CMV) PCR test at baseline
  • Pregnant or breast-feeding patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02369016

Layout table for location information
Jaú, Sao Paulo, Brazil, 17210-120
São Paulo, Sao Paulo, Brazil, 08270-120
Sao Paulo, Brazil
Plovdiv, Bulgaria, 4002
Athens, Greece, 115 26
Bologna, Emilia-Romagna, Italy, 40138
Genova, Liguria, Italy, 16132
Korea, Republic of
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 03080
Jeollabuk-do, Korea, Republic of, 561-712
Jeollanam-do, Korea, Republic of, 58128
Seoul, Korea, Republic of, 03722
Seoul, Korea, Republic of, 05505
Gdynia, Poland, 81-519
Russian Federation
Kazan, Russian Federation, 420029
Kemerovo, Russian Federation, 650066
Moscow, Russian Federation, 123182
Omsk, Russian Federation, 644013
Penza, Russian Federation, 440071
South Africa
Johannesburg, Gauteng, South Africa, 2013
Taipei, Taiwan, 100
Istanbul, Turkey, 34093
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT02369016    
Other Study ID Numbers: 17322
2014-000925-19 ( EudraCT Number )
First Posted: February 23, 2015    Key Record Dates
Last Update Posted: April 27, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bayer:
indolent Non-Hodgkin lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases